EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Platinum-based chemotherapy was previously the first-choice treatment for lung cancer. The discovery of epidermal growth factor receptor (EGFR) gene mutations and the development of EGFR tyrosine kinase inhibitors (TKIs) marked the beginning of the targeted therapy era for non-small-cell lung cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Jiabao, Li, Hongle, Ma, Shuxiang, He, Zhen, Yang, Sen, Hao, Lidan, Zhou, Hanqiong, Zhang, Zhe, Han, Jing, Wang, Li, Wang, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008900/
https://www.ncbi.nlm.nih.gov/pubmed/35418149
http://dx.doi.org/10.1186/s40364-022-00372-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008900/
https://www.ncbi.nlm.nih.gov/pubmed/35418149
http://dx.doi.org/10.1186/s40364-022-00372-6

Ejemplares similares